RxDoctor Payments Data

Terence Grogan, DO

Family Medicine · Indianapolis, INNPI 1427163492

Payments from drug & device makers

$1,419in general payments, 2019–2025

Across 96 payments — averaging $14.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$208
  • AstraZeneca$193
  • Novo Nordisk$180
  • Lilly USA, LLC$166
  • Abbott$154
  • Otsuka America Pharmaceutical, Inc.$109
  • plus $409 from 12 others

What the payments were for

  • Food & beverage$1,419100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,419 in reported general payments places this provider in the 65th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$819
Medicare patients
73
Services billed
101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide233$225,876
Trelegy ElliptaFluticasone/Umeclidin/Vilanter137$98,643
JardianceEmpagliflozin86$90,534
EliquisApixaban74$64,949
RybelsusSemaglutide39$59,586
MounjaroTirzepatide42$52,019
PercocetOxycodone Hcl/Acetaminophen12$44,338
FarxigaDapagliflozin Propanediol17$26,091
JanuviaSitagliptin Phosphate24$25,635
XareltoRivaroxaban25$25,166
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$19,340
Breo ElliptaFluticasone/Vilanterol32$15,210
LinzessLinaclotide12$15,089
Combivent RespimatIpratropium/Albuterol Sulfate30$14,497
Lantus SolostarInsulin Glargine,hum.Rec.Anlog89$14,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$180$285,462272 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$44$127,016191 claims
PfizerEliquis$103$64,94974 claims
Lilly USA, LLCMounjaro$166$52,01942 claims
AstraZenecaFarxiga$193$26,09117 claims
AbbVieLinzess$208$15,08912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →